Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial
Survival outcomes for patients with recurrent or advanced cervical cancer are poor. GX-188E vaccination has been shown to induce human papillomavirus (HPV) T-cell responses and cervical lesion regression in patients with cervical precancer. Treatment with GX-188E therapeutic vaccine plus pembrolizumab was safe and treatment-related adverse events were manageable.
